Chemical Information
Antiviral agent ID	DrugRepV_3461
Antiviral agent name	Hesperadin
IUPAC Name	N-[2-hydroxy-3-[C-phenyl-N-[4-(piperidin-1-ylmethyl)phenyl]carbonimidoyl]-1H-indol-5-yl]ethanesulfonamide
SMILES (canonical)	CCS(=O)(=O)NC1=CC2=C(C=C1)NC(=C2C(=NC3=CC=C(C=C3)CN4CCCCC4)C5=CC=CC=C5)O
Molecular Formula	C29H32N4O3S
Molecular Weight (g/mol)	516.66
InChl	InChI=1S/C29H32N4O3S/c1-2-37(35,36)32-24-15-16-26-25(19-24)27(29(34)31-26)28(22-9-5-3-6-10-22)30-23-13-11-21(12-14-23)20-33-17-7-4-8-18-33/h3,5-6,9-16,19,31-32,34H,2,4,7-8,17-18,20H2,1H3
Common Name	Hesperidin
Synonyms	Hesperadine | GTPL8354 | MFCD18074526 | J-523310
Structural Information
Clinical Information
Category	Anticancer
Primary Indication (Clinical trial phases)	Approved, Investigational
Biological Information
Secondary Indication	Influenza virus (IAV) H3N2 A/California/02/2014 (H3N2)
Secondary Indication (Approaches)	Experimental
Secondary Indication (Methods)	In-vitro
Secondary Indication (Model system) [cell lines/ animal models]	MDCK
Secondary Indication (Mode of viral infection)	Adsorption
Secondary Indication (Viral titer)	100 PFU
Secondary Indication (Mode of drug delivery)	Culture
Secondary Indication (Time of drug delivery)	Post infection
Secondary Indication (Duration of drug delivery)	48 hours
Secondary Indication (Drug concentration)	1.80 ± 0.42 μM
Secondary Indication (Cell based assay)	Plaque assay
Secondary Indication (Change)	Decrease
Secondary Indication (Type of Inhibition)	EC50 [ 50 % ]
Secondary Indication (Cytotoxicity)	21.3 ± 0.8 μM
Reference	Hu Y, Zhang J, Musharrafieh R, Hau R, Ma C, Wang J..Chemical Genomics Approach Leads to the Identification of Hesperadin, an Aurora B Kinase Inhibitor,.Int J Mol Sci. 2017 Sep 8;18(9). pii: E1929. doi: 10.3390/ijms18091929. PMID:28885544
Comment	Oseltamivir Resistant